These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 37662943)

  • 1. Corrigendum: Cross-reactive humoral and CD4
    Martel F; Cuervo-Rojas J; Ángel J; Ariza B; González JM; Ramírez-Santana C; Acosta-Ampudia Y; Murcia-Soriano L; Montoya N; Cardozo-Romero CC; Valderrama-Beltrán SL; Cepeda M; Castellanos JC; Gómez-Restrepo C; Perdomo-Celis F; Gazquez A; Dickson A; Brien JD; Mateus J; Grifoni A; Sette A; Weiskopf D; Franco MA
    Front Immunol; 2023; 14():1274753. PubMed ID: 37662943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
    Castro EF; Acosta J; Moriena L; Rios Medrano M; Tejerina Cibello M; Codino E; Taborda MÁ; Álvarez DE; Cavatorta AL
    mSphere; 2023 Jun; 8(3):e0066222. PubMed ID: 37070983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern.
    Ruhl L; Kühne JF; Beushausen K; Keil J; Christoph S; Sauer J; Falk CS
    Front Immunol; 2023; 14():1120010. PubMed ID: 37033958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants.
    Koutsakos M; Lee WS; Reynaldi A; Tan HX; Gare G; Kinsella P; Liew KC; Taiaroa G; Williamson DA; Kent HE; Stadler E; Cromer D; Khoury DS; Wheatley AK; Juno JA; Davenport MP; Kent SJ
    Immunity; 2022 Jul; 55(7):1316-1326.e4. PubMed ID: 35690062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erratum: Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity.
    Frontiers Production Office
    Front Immunol; 2023; 14():1249100. PubMed ID: 37503347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine.
    Gallais F; Gantner P; Planas D; Solis M; Bruel T; Pierre F; Soulier E; Rossolillo P; Fourati S; Sibilia J; Schwartz O; Fafi-Kremer S
    Front Immunol; 2022; 13():790212. PubMed ID: 35281046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment.
    Woopen C; Dunsche M; Haase R; Raposo C; Pedotti R; Akgün K; Ziemssen T
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
    Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
    mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies.
    Mazzoni A; Vanni A; Spinicci M; Lamacchia G; Kiros ST; Rocca A; Capone M; Di Lauria N; Salvati L; Carnasciali A; Mantengoli E; Farahvachi P; Zammarchi L; Lagi F; Colao MG; Liotta F; Cosmi L; Maggi L; Bartoloni A; Rossolini GM; Annunziato F
    J Clin Invest; 2022 Mar; 132(6):. PubMed ID: 35139036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
    Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
    Front Immunol; 2022; 13():981350. PubMed ID: 36059485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
    Seekircher L; Bánki Z; Kimpel J; Rössler A; Schäfer H; Falkensammer B; Bante D; Forer L; Schönherr S; ; Harthaller T; Sacher M; Ower C; Tschiderer L; Ulmer H; Krammer F; von Laer D; Borena W; Willeit P
    Lancet Microbe; 2023 Aug; 4(8):e612-e621. PubMed ID: 37354911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
    Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
    Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
    McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
    Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination.
    Casado JL; Vizcarra P; Martín-Hondarza A; Blasco M; Grandal-Platero M; Haemmerle J; Fernández-Escribano M; Vallejo A
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection.
    Pušnik J; Monzon-Posadas WO; Zorn J; Peters K; Baum M; Proksch H; Schlüter CB; Alter G; Menting T; Streeck H
    Nat Commun; 2023 Feb; 14(1):572. PubMed ID: 36732523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
    Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
    Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients.
    Thümmler L; Gäckler A; Bormann M; Ciesek S; Widera M; Rohn H; Fisenkci N; Otte M; Alt M; Dittmer U; Horn PA; Witzke O; Krawczyk A; Lindemann M
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.